Jpmorgan Chase & CO Aadi Bioscience, Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,478 shares of AADI stock, worth $2,852. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,478
Previous 4,237
65.12%
Holding current value
$2,852
Previous $8,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding AADI
# of Institutions
57Shares Held
15.6MCall Options Held
15KPut Options Held
3.1K-
Avoro Capital Advisors LLC New York, NY2.85MShares$5.5 Million0.13% of portfolio
-
Qvt Financial LP New York, NY2.31MShares$4.47 Million0.72% of portfolio
-
Bml Capital Management, LLC Zionsville, IN2.1MShares$4.05 Million4.12% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$3.57 Million8.31% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.15MShares$2.21 Million1.96% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $40.6M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...